Update on Non-Statin Lipid-Lowering Therapies from ESC 2025
Update on CD19-Targeted CAR T-cell Therapy to Treat Severe Refractory Systemic Lupus Erythematosus (SLE)
The Potential for Targeted Inhibition of Factor XI/XIa to Provide Safe and Effective Protection from a Secondary Ischemic Noncardioembolic Stroke
Update on CD19-Targeted CAR T-cell Therapy to Treat Severe Refractory Systemic Lupus Erythematosus (SLE)
New Phase 3 Data from ESC on Management of Uncontrolled or Treatment-Resistant Hypertension with an Aldosterone Synthase Inhibitor
New Phase 3 Data from ESC on Management of Uncontrolled or Treatment-Resistant Hypertension with an Aldosterone Synthase Inhibitor
Is There a Safe and Effective Anticoagulation Strategy for Secondary Prevention of Non-Cardioembolic Ischemic Stroke?
Non-Statin Cholesterol Management Update
Optimizing Care for HCM Patients: Evidence-Based, Pathology-Targeted Management for All
The Evolving Role of CAR T Therapeutics in the Management of MS Neuroinflammation
Clinical Update on Anti-CD20 Therapeutics for Patients with Relapsing Multiple Sclerosis
Unlocking “Pro” Secrets: Optimizing Echocardiographic Imaging in the Diagnosis and Management of Hypertrophic Cardiomyopathy
LIVE UPDATE FROM ACC25: More Support for the “Factor XI Hypothesis”
MANAGEMENT OF PSVT: UPDATE FROM ACC25
From PCP to Nephrologist & Supportive Patient Education to Achieve Continuity of Care and Adherence to Optimal Treatment Strategies in IgA Nephropathy
Unmet Needs in the Management of Atrial Fibrillation (AF)
LIVE UPDATE FROM AHA24: What do we know about antiplatelets added to anticoagulation in patients with AF?
Best Practices for Implementing Dual Endothelin Angiotensin Receptor Antagonist Therapeutics in Patients with IgAN
Update on Emerging Anticoagulants
IgAN Update Fall 2024